← All trials
NCT01806675
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2013
- Primary completion
- Mar 1, 2018
- Completion date
- Mar 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Stanford UniversityLead sponsor
- Stanford UniversityOverall official - principal investigator
- Stanford UniversitySponsor investigator
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
- Nasopharyngeal Carcinoma
- Brain Neoplasms
- Breast Neoplasms
- Basal Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Colonic Neoplasms
- Carcinoma, Adenoid Cystic
- Glioblastoma
- Granuloma
- Hypopharyngeal Neoplasms
- Laryngeal Neoplasms
- Mouth Neoplasms
- Nasopharyngeal Neoplasms
- Neoplasm Metastasis
- Neoplasms
- Neuroblastoma
- Oropharyngeal Neoplasms
- Pancreatic Neoplasms
- Salivary Gland Neoplasms
- Tongue Neoplasms
- Colorectal Neoplasms
- Carcinoma, Mucoepidermoid
- Papilloma, Inverted
- Gliosarcoma
- Breast Neoplasms, Male
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.